ZANTAC 150 Drug Patent Profile
✉ Email this page to a colleague
When do Zantac 150 patents expire, and when can generic versions of Zantac 150 launch?
Zantac 150 is a drug marketed by Glaxosmithkline, Glaxo Grp Ltd, and Chattem Sanofi. and is included in four NDAs.
The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 150
A generic version of ZANTAC 150 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
Summary for ZANTAC 150
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 22 |
Patent Applications: | 2,243 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ZANTAC 150? | ZANTAC 150 excipients list |
DailyMed Link: | ZANTAC 150 at DailyMed |
Recent Clinical Trials for ZANTAC 150
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Food and Drug Administration (FDA) | Phase 1 |
Spaulding Clinical Research LLC | Phase 1 |
Dalhousie University | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ZANTAC 150
US Patents and Regulatory Information for ZANTAC 150
Expired US Patents for ZANTAC 150
International Patents for ZANTAC 150
See the table below for patents covering ZANTAC 150 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | A322880 | ⤷ Try a Trial | |
Australia | 2751977 | ⤷ Try a Trial | |
Hong Kong | 55780 | AMINOALKYL FURAN DERIVATIVES | ⤷ Try a Trial |
South Korea | 940006271 | ⤷ Try a Trial | |
Denmark | 167794 | ⤷ Try a Trial | |
Germany | 2734070 | ⤷ Try a Trial | |
Saudi Arabia | 22 | تركيبات صيدلية فوارة | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |